Analytical Reagents
25 compounds
Enclomiphene
Enclomiphene is a selective estrogen receptor modulator (SERM) studied for how it influences the hypothalamic pituitary gonadal axis by reducing estrogen receptor signaling at the hypothalamus and pituitary. In research contexts, it is primarily explored for its ability to increase LH and FSH output, which can raise endogenous testosterone production in responsive models. It is often discussed as the trans isomer associated with a more stimulating endocrine profile compared with mixed clomiphene isomer products.
SLU-PP-332
SLU-PP-332 is a small molecule research compound most often discussed as an “exercise mimetic” style agent in preclinical models. Interest centers on its potential to shift cellular energy metabolism toward greater oxidative output, mitochondrial biogenesis signaling, and endurance type adaptations, even without an exercise stimulus. Most of the attention around SLU-PP-332 comes from preclinical performance and metabolic research, not long term human data.
Aminotadalafil
Aminotadalafil is a tadalafil related PDE5 inhibitor compound studied in the same general research lane as tadalafil. It is most commonly framed around erectile function signaling and blood flow related endpoints, with additional research interest in gym performance adjacent vasodilation effects and mild blood pressure modulation signals.
Clenbuterol
Clenbuterol is a beta-2 adrenergic agonist best known in research for its bronchodilator activity and strong stimulation of adrenergic signaling. In experimental settings, beta-2 receptor activation is used to study airway smooth-muscle relaxation, sympathetically driven metabolic changes, and downstream cyclic adenosine monophosphate (cAMP) signaling across multiple tissues. Clenbuterol is not approved for human use in several jurisdictions and is frequently associated with misuse. Research discussions therefore emphasize cardiovascular stress, electrolyte disturbances, and receptor desensitization.
BAM-15
BAM-15 is a small molecule mitochondrial uncoupler used in research to study energy balance, cellular bioenergetics, and metabolic signaling. It is primarily investigated for its ability to dissipate the mitochondrial proton gradient, lowering oxidative phosphorylation efficiency and increasing substrate oxidation demand in experimental models. Because uncoupling directly affects heat production and cellular energy status, BAM-15 is generally treated as a higher risk research compound that requires strict controls and monitoring in study design.
Nortadalafil
Nortadalafil is a tadalafil related analog and metabolite class compound sometimes referenced in analytical chemistry contexts when characterizing tadalafil like structures. In research, it is generally discussed as a PDE5 inhibitor associated analog and is typically examined for structure activity relationships, analytical identification, and pharmacology adjacent modeling rather than as a primary clinical agent.
O-304 (ATX-304)
O-304 (ATX-304) is an investigational research compound typically encountered in laboratory and analytical contexts. It is primarily explored for its potential effects on metabolic signaling pathways and energy regulation in preclinical models, with interest often centered on how it may influence substrate utilization, body composition variables, and performance related endpoints depending on study design. Available Formats
Arimistane
Arimistane is a steroidal compound researched primarily for its potential aromatase-inhibiting activity. In research contexts, it is explored for its ability to reduce the enzymatic conversion of androgens into estrogens, which may alter the estrogen-to-androgen balance depending on baseline endocrine status and study design. Arimistane is often discussed in supplementation contexts as a nonprescription aromatase inhibitor. However, robust human clinical data are limited, so many claims are based on mechanistic rationale and preclinical-style interpretation.
Amlexanox
Amlexanox is a small-molecule compound researched for its anti-inflammatory and immunomodulatory properties. In research contexts, it is most often discussed for its potential to inhibit TBK1 and IKKε signaling pathways, which are involved in inflammatory tone and metabolic regulation in certain experimental models. Historically, Amlexanox has also been used in select regions for inflammatory or allergic conditions, which is one reason it remains of interest in translational research.
Mirodenafil
Mirodenafil is a phosphodiesterase type 5 (PDE5) inhibitor researched for its ability to modulate nitric-oxide and cyclic guanosine monophosphate (cGMP) signaling, as well as smooth-muscle tone. In research contexts, it is primarily explored for its effects on vascular smooth-muscle relaxation, perfusion-related endpoints, and erectile-function models in which PDE5 activity is a key variable. As a PDE5-inhibitor-class compound, Mirodenafil is often discussed alongside other agents that influence cyclic-nucleotide signaling and endothelial function.
ITPP
ITPP (myo-inositol trispyrophosphate) is a small-molecule research compound studied for its ability to modulate hemoglobin oxygen affinity. In research contexts, it is primarily explored for its potential to shift the oxygen–hemoglobin dissociation curve and increase oxygen unloading in peripheral tissues. This may alter hypoxia signaling, perfusion-dependent outcomes, and endurance-related endpoints depending on the experimental model. ITPP is often discussed in hypoxia-biology research because tissue oxygen delivery can act as an upstream driver of pathways such as hypoxia-inducible factor (HIF) signaling and downstream metabolic adaptation.
Acetildenafil
Acetildenafil is a synthetic phosphodiesterase type 5 (PDE5) inhibitor analog researched for its ability to influence the nitric-oxide and cyclic guanosine monophosphate (cGMP) pathway in vascular smooth muscle. In research contexts, it is primarily explored for its potential to increase cGMP signaling by inhibiting PDE5, which may amplify nitric-oxide-mediated vasodilation responses in responsive models. Acetildenafil is commonly discussed as a sildenafil-related analog, with ongoing analytical interest in its potency, selectivity, metabolism, and safety profile relative to better-characterized PDE5 inhibitors.
Mirabegron
Mirabegron is a beta-3 adrenergic receptor agonist researched for its ability to modulate sympathetic signaling in target tissues. In research contexts, it is primarily explored for its effects on detrusor smooth-muscle relaxation and urinary-storage dynamics through beta-3 receptor activation, as well as for its broader downstream effects on cyclic adenosine monophosphate (cAMP) signaling in responsive models. Because beta-adrenergic signaling can influence multiple organ systems, Mirabegron is also investigated in metabolic and cardiovascular research designs in which adrenergic tone is a controlled variable.
3,5-Diiodo-L-thyronine (T2)
3,5-Diiodo-L-thyronine (T2) is a thyroid-hormone metabolite researched for its potential to influence cellular energy metabolism. In research contexts, T2 is primarily explored for its effects on mitochondrial function, lipid handling, and metabolic-rate signaling, often in models in which thyroid-axis activity and energy expenditure are key experimental variables. Unlike T3- and T4-focused paradigms that strongly involve nuclear thyroid-receptor signaling, T2 is frequently discussed as having more rapid, non-genomic mitochondrial effects in certain study designs. However, observed outcomes depend heavily on model selection, exposure, and measured endpoints.
GC-1 Sobetirome
GC-1 Sobetirome is a thyroid-hormone receptor agonist researched for its preferential activity at thyroid receptor beta. In research contexts, it is primarily explored for its potential to influence lipid metabolism, hepatic gene expression, and energy-expenditure-related endpoints, with the goal of capturing thyroid-like metabolic effects while reducing thyroid receptor alpha-driven effects that are more strongly associated with cardiac stimulation. GC-1 is commonly discussed in metabolic research as a tool compound for studying thyroid-receptor selectivity, cholesterol handling, and fat-loss-related pathways.
4-Hydroxytamoxifen
4-Hydroxytamoxifen is a selective estrogen receptor modulator (SERM) researched as one of tamoxifen’s primary active metabolites. In research contexts, it is explored for its high-affinity binding to estrogen receptors and its ability to modulate estrogen-responsive transcription in a tissue-selective manner. It is often used as a direct tool compound in estrogen-receptor-signaling studies because it bypasses the metabolic conversion required when parent tamoxifen is used in certain models.
Y-134 (Raloxifene Analog)
Y-134 is a research compound positioned as a raloxifene analog and commonly discussed within the broader selective estrogen receptor modulator (SERM) class. In research contexts, it is typically explored as a tool for modulating estrogen-receptor signaling with tissue-selective activity. Its downstream effects may therefore differ across tissues based on receptor-subtype expression, cofactor availability, and baseline endocrine conditions. Because Y-134 is referenced as a raloxifene analog, it is generally studied for estrogen-receptor-modulation patterns that may resemble raloxifene-like signaling profiles in certain experimental designs rather than for direct estrogen-agonist activity.
Endoxifen
Endoxifen is a selective estrogen receptor modulator (SERM) and one of the primary active metabolites associated with tamoxifen research. In research contexts, it is explored for its ability to bind estrogen receptors and modulate estrogen signaling in a tissue-dependent manner. Because it is already an active metabolite, Endoxifen is often discussed in studies where variability in tamoxifen metabolism is a confounding factor, particularly in models examining estrogen-receptor signaling intensity and downstream gene expression. Endoxifen is commonly positioned as a more direct estrogen-receptor modulator than parent tamoxifen because it does not rely on metabolic conversion to reach an active state within the experimental system.
Roxadustat
Roxadustat is a small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) studied for its ability to stabilize hypoxia-inducible factors under normoxic conditions. In research contexts, it is primarily explored for its downstream effects on erythropoietin (EPO) signaling, iron-handling pathways, and hypoxia-responsive gene programs that influence red-blood-cell production and oxygen-delivery variables. Rather than directly supplying EPO, Roxadustat is investigated as a hypoxia-pathway modulator capable of altering multiple transcriptional targets involved in erythropoiesis and iron metabolism, depending on study design.
SM04554
SM04554 is an investigational small molecule studied as a topical Wnt-pathway modulator in androgenetic alopecia research models. Wnt signaling is a conserved biological pathway involved in tissue repair and regeneration, and reduced Wnt activity has been reported in certain androgenetic alopecia research contexts. According to published sponsor materials, the complete mechanism of action has not been fully defined and remains under investigation.
RU58841
RU58841 (CAS 154992-24-2) is a laboratory-grade nonsteroidal antiandrogen developed as a synthetic androgen receptor (AR) antagonist, designed to competitively block androgen binding at the receptor level without inhibiting testosterone or dihydrotestosterone (DHT) synthesis. In research settings it is investigated for AR binding, receptor-level antagonism, and downstream modulation of androgen-dependent gene expression, particularly in skin and hair follicle models. RU58841 from Kimera is supplied as a 5% topical carrier solution at 50 mg/mL in a 30 mL bottle and is explicitly not approved for human or veterinary use.
CB-03-01
CB-03-01 (clascoterone, CAS 19608-29-8) is a laboratory-grade synthetic steroidal antiandrogen characterized by localized androgen receptor antagonism with rapid metabolic inactivation, making it suitable for tissue-selective androgen signaling research rather than systemic hormone suppression studies. In research settings it is investigated for peripheral androgen receptor blockade, androgen-responsive gene modulation, and skin- and follicle-focused hormone signaling models. CB-03-01 from Kimera is supplied as a liquid research material at 50 mg/mL in a mixed solvent system and is explicitly not approved for human or veterinary use.
GSK-2881078
GSK-2881078 is an investigational selective androgen receptor modulator (SARM) studied for its potential to promote anabolic signaling in muscle and bone while aiming to reduce the broader androgenic profile associated with traditional androgens. In research contexts, it is primarily explored in models of lean-mass preservation, physical-function endpoints, and catabolic states in which androgen-receptor signaling is a key experimental variable. Because SARMs are nonsteroidal androgen-receptor ligands, GSK-2881078 is often discussed as a research tool for isolating androgen-receptor-mediated effects with greater tissue selectivity than testosterone-based paradigms.
SLU-PP-915
SLU-PP-915 is a synthetic small-molecule pan-agonist of the estrogen-related receptor family (ERRα, ERRβ, and ERRγ). Developed at Saint Louis University as a second-generation analog of SLU-PP-332, it was designed around a phenylboronic acid pharmacophore to retain pan-ERR potency while improving microsomal metabolic stability and oral bioavailability. It is studied for its role in promoting mitochondrial biogenesis, oxidative metabolism, and exercise-mimetic transcriptional programs, with particular interest in its application to heart failure models, skeletal muscle research, and endurance capacity investigation.
SANA (MVD1)
SANA (MVD1) is the research designation for 5-(2-nitroethenyl)salicylic acid, a small-molecule nitroalkene derivative of salicylate under active investigation for its role in adipose tissue thermogenesis and energy expenditure. It operates through a mechanistic framework entirely distinct from incretin-based research tools such as GLP-1, GIP, and dual or triple agonists, which work primarily through receptor-mediated hormone signaling. SANA instead targets creatine metabolism within adipose tissue to drive a form of thermogenesis that does not depend on UCP1 or AMPK, positioning it as a novel class of metabolic research probe.